EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study

Samar Alharbi iD, Delal Alkortas, Dema Alissa iD, Aziza Ajlan iD, Zinah Alabdulkarim, Hala Joharji iD, Khalid Alhasan iD, Edward Bentz Devol, Dalia Obeid iD, Ahmed Al-Jedai

Viruses · 28.02.2026 · 18 (3) · 297

DOI: 10.3390/v18030297 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Viruses, online erschienen am 28.02.2026. Verfasst von Samar Alharbi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Valganciclovir, Cytomegalovirus Infections, Antiviral Agents, Transplant Recipients. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal valganciclovir dosing for cytomegalovirus (CMV) prophylaxis in pediatric solid organ transplant recipients remains difficult due to variable pharmacokinetics. This study compared the efficacy and safety of three dosing strategies: body surface area (BSA)-based, weight-based, and Pescovitz algorithm-based dosing. This retrospective cohort study included pediatric patients aged ≤14 years who underwent kidney or liver transplantation between 2010 and 2018 and received valganciclovir for CMV prophylaxis. The primary outcome was the comparative effectiveness of the three dosing approaches in preventing CMV infection and disease. The study included 150 patients, with 50 in each group. CMV infection occurred more frequently in the BSA-based group than in the Pescovitz algorithm-based or weight-based groups. Among patients who developed CMV DNAemia, CMV disease occurred in 54%, 28%, and 50% of patients in the BSA-based, Pescovitz algorithm-based, and weight-based groups, respectively. No tissue-invasive CMV disease was observed within 12 months after transplantation. All groups showed acceptable safety profiles, and no patients discontinued therapy due to hematologic adverse events. Weight-based dosing was associated with lower CMV infection and disease rates than BSA-based dosing and Pescovitz algorithm-based dosing, with similar safety. In pediatric solid organ transplant recipients, valganciclovir dosing strategy was not independently associated with CMV infection after adjustment. Age emerged as the sole independent predictor of CMV risk, underscoring the predominance of patient-related factors in CMV prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValganciclovirCytomegalovirus InfectionsAntiviral AgentsTransplant RecipientsOrgan TransplantationHumansFemaleChildMaleRetrospective StudiesChild, PreschoolAdolescentCytomegalovirusInfantLiver TransplantationAlgorithmsBody Surface AreaKidney Transplantation

Stichwörter der Autor:innen

cytomegaloviruskidney transplantliver transplantpediatric transplantprophylaxisvalganciclovir

Substanzen

ValganciclovirAntiviral Agents

Autor:innen und Institutionen

  • Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia.
  • College of Pharmacy, Al-Faisal University, Riyadh 11533, Saudi Arabia.
  • College of Medicine, King Saud University, Riyadh 11362, Saudi Arabia.
  • Pediatric Department, King Saud University Medical City, Riyadh 11362, Saudi Arabia.
  • Department of Biostatistics, Epidemiology & Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.

ORCID-Profile: Samar Alharbi, Dema Alissa, Aziza Ajlan, Hala Joharji, Khalid Alhasan, Dalia Obeid

Zitieren

APA

Alharbi, S., Alkortas, D., Alissa, D., Ajlan, A., Alabdulkarim, Z., Joharji, H., Alhasan, K., Devol, E. B., Obeid, D., & Al-Jedai, A. (2026). Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study. Viruses, 18(3), 297. https://doi.org/10.3390/v18030297

Vancouver

Alharbi S, Alkortas D, Alissa D, Ajlan A, Alabdulkarim Z, Joharji H, et al. Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study. Viruses. 2026;18(3):297. doi:10.3390/v18030297

BibTeX
@article{Alharbi2026,
  author = {Alharbi, Samar and Alkortas, Delal and Alissa, Dema and Ajlan, Aziza and Alabdulkarim, Zinah and Joharji, Hala and Alhasan, Khalid and Devol, Edward Bentz and Obeid, Dalia and Al-Jedai, Ahmed},
  title = {Valganciclovir Dosing Strategies for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients: A Comparative Single-Center Study},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {297},
  doi = {10.3390/v18030297}
}
Kostenlos starten →